ReviewBlood transfusion = Trasfusione del sangue2016
The evolution of anticoagulant therapy.
Review in Blood transfusion = Trasfusione del sangue, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis.Frontiers in pharmacology · 2023Pooled it
- [Comparison of efficacy and safety between new oral anticoagulants and traditional anticoagulants in patients with liver cirrhosis requiring anticoagulant therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Pooled it
- A Single-blind, Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to Assess the Bioequivalence between Two Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Mexican Volunteers.Clinical pharmacology in drug development · 2022Trial
- Hemorrhagic Events Associated With Direct Oral Anticoagulants: Frequency and Management.Cureus · 2025Article
- Dose-reduced apixaban for secondary prophylaxis in patients with severe obesity: a single center analysis.Blood advances · 2025Article
- A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.International journal of molecular sciences · 2025Article
- Update on Patient Self-Testing with Portable and Wearable Devices: Advantages and Limitations.Diagnostics (Basel, Switzerland) · 2024Article
- Factor Xa inhibitors versus low-molecular-weight heparin for preventing coagulopathy following COVID-19: a systematic review and meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2024Review
- Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review.Cureus · 2024Review
- Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition.Current research in pharmacology and drug discovery · 2024Review
- Pharmacogenomic Considerations for Anticoagulant Prescription in Patients with Hereditary Haemorrhagic Telangiectasia.Journal of clinical medicine · 2023Article
- Systematic review on the effects of the discontinuation of the anticoagulant therapy and the postoperative bleeding, in patients under new oral anticoagulants after dental extraction.Journal of clinical and experimental dentistry · 2023Review
- Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma.Journal of medicinal chemistry · 2023Article
- A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability.Pharmaceutics · 2023Article
- Marine Biological Macromolecules and Chemically Modified Macromolecules; Potential Anticoagulants.Marine drugs · 2022Review
- Proximal femur fractures in patients taking anti-coagulants: has anything changed?EFORT open reviews · 2022Review
- Editorial for the Special Issue of Monitoring Anticoagulants.Biomedicines · 2022Article
- Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran.Frontiers in pediatrics · 2022Review
- Dry Needling and Antithrombotic Drugs.Pain research & management · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial and venous thromboembolism are leading causes of morbidity and mortality around the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight heparins) and vitamin K antagonists have been the leading therapeutic medical options for the treatment and prevention of thromboembolic disorders. Nevertheless, the many limitations of these traditional anticoagulants have fuelled the search for novel agents over the past 15 years, and a new class of oral anticoagulants that specifically target activated factor X and thrombin has been developed and is now commercially available. In this narrative review, the evolution of anticoagulant therapy is summarised, with a focus on newer oral anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.